🔎 Trials Near Me

Home › Diabetes › NCT06726590

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

RecruitingObservational study

The Texas Interprofessional Pharmacogenomics Registry and Repository

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* The study will invite patients who are eligible for PGX workup/PGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or
* Individuals taking blood pressure or depression medications, even if less than five medications.
* Ability to understand and give consent.
* Able to consent to donate blood and/or urine samples and buccal swabs.
* Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions.
* Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community.
* All genders.
* Any age over 18 years.

Exclusion Criteria:

* Individuals admitted to hospice.
* Declines to participate or interact with staff/share their medical status.
* A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.,
* Individuals who are unable or unwilling to provide consent.
* Unable to verbally communicate and comprehend English language

About the study

This program collects genetic and health information to help doctors choose the right medications for patients.

Sponsor: Texas A&M University · Participants: 3,000 · Started: 2025-11

Contact the study team

Official record on ClinicalTrials.gov — NCT06726590

Locations in the U.S.

TexasTexas A&M Family Care, Bryan

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.